Lack of knowledge about what works best where, how to improve delivery and assess impact

Countries and funding institutions require policy guidelines to drive implementation

Challenges preventing access to drugs and diagnostic tests in target settings

Evidence

- Characterize target settings
  - Describe settings based on transmission, ecology, and human movement patterns. This group will focus on moderate and low transmission settings.

- Determine key evidence gaps
  - Determine settings where empirical and modeling evidence is needed.

- Establish cost-effective scenarios in target settings
  - Establish the benefits of MDA & SAT in target settings, including cross-border regions and outbreak scenarios.

  - Determine best interventions and drugs for target settings:
    - Drugs (e.g. DP, AS-PYR, SLD PQ, RTS, S)
    - Diagnostic tools (e.g. HSRDTs, LAMP, serology)
    - Co-interventions (e.g. reactive vector control, LSM)
    - Surveillance (e.g. how focally to target)

- Improving delivery:
  - Ensuring coverage within target populations
  - Community mobilization to encourage adherence and acceptance

  - Build consensus on costing methods, measurements of impact, and trial endpoints, include M&E for program implementation and pharmacovigilance.

Policy & Financing

- WHO to provide policy guidance
  - Collate necessary evidence to inform WHO Evidence Review Group (e.g. cost, effectiveness, efficacy and sustainability, etc.).

- Facilitate national-level drug policy changes
  - Develop a framework for programs that details when to add antimalarial drugs to national policies and/or treatment guidelines.

- Address regulatory barriers
  - Identify non-registered commodities and commodities facing registration delays, such as multiple ACTs for different use scenarios.

  - Establish pathways to accelerate registration and/or procurement methods (e.g. the use of centralized networks).

Access to Commodities

- Optimize supply chain
  - Ensure access of commodities to remote and rural areas.

GOAL

- Generate evidence to support policy

- Countries implement appropriate antiparasite measures

- Improve access to needed tools

THEME

PATHWAYS

GAP